A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (OS) with axitinib dose titration. | Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration Analysis from a randomised double-blind phase II study